Jean-Pierre Delord

12PUBLICATIONS
40CO-AUTHORS
Gene and molecular therapyMedical devicesMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 01, 2026
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Capucine Baldini, Philippe A Cassier, Jean-Pierre Delord

|Mar 27, 2023
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.

Michael R Paillasse, Michael Esquerré, Florie A Bertrand

|Apr 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.

Vivek Subbiah, Irene Braña, Alessandra Longhi

|Feb 11, 2021
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Daniel P Petrylak, Yohann Loriot, David R Shaffer

|Dec 04, 2020
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.

Anne Montfort, Thomas Filleron, Mathieu Virazels

|Sep 30, 2020
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Christophe Le Tourneau, Yungan Tao, Carlos Gomez-Roca

Pageof 2

Frequent Collaborators

2 joint publications

Philippe Rochaix

1 joint publications

David I Quinn

1 joint publications

Viktor Grünwald

1 joint publications

Ugo De Giorgi